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Many  first-line  cancer  drugs  are  natural  products  or  are  derived  from  them  by  chemical 
modification. The trioxacarcins are an emerging class of molecules of microbial origin with potent 
antiproliferative effects, which may derive from their ability to covalently modify duplex DNA. All 
trioxacarcins appear to be derivatives of a non-glycosylated natural product known as DC-45-A2. 
To explore the potential of the trioxacarcins for the development of small-molecule drugs and 
probes, we have designed a synthetic  strategy towards the trioxacarcin scaffold that enables 
access to both the natural trioxacarcins and non-natural structural variants. Here we report a 
synthetic route to DC-45-A2 from a differentially protected precursor, which in turn is assembled 
in  just  six  steps  from  three  components  of  similar  structural  complexity.  The  brevity  of  the 
sequence arises from strict adherence to a plan in which strategic bond-pair constructions are 
staged at or near the end of the synthetic route. 
 
\body 
  The trioxacarcins are highly concatenated, densely oxygenated molecules encoded within the genes of 
various  streptomycetes  and  potently  inhibit  the  growth  of  cultured  human  cancer  cell  lines  (1–4). 
Approximately 20 individual trioxacarcins have been structurally characterized; all appear to be built upon 
or closely related to the natural product DC-45-A2 (1) (5). The diversity of the trioxacarcin class is well 
represented  by  the  four  compounds  that  are  depicted  in  Fig.  1  alongside  the  anthracycline  antibiotic 
daunomycin  (daunorubicin,  long  used  in  chemotherapy  for  acute  myelogenous  leukemias)  and 
nogalamycin, presented in a manner that emphasizes their structural similarities. The trioxacarcins however 
                                                              




have  unique  glycosylation  patterns,  contain  a  distinct  linear  aromatic  core,  and  bear  as  their  most 
distinguishing feature a highly unusual condensed polycyclic tris-ketal containing a spiro-epoxide. The 
latter is implicated to be key to the observed antiproliferative effects of the trioxacarcins, for it has been 
shown to serve as the point of covalent attachment of trioxacarcin A (6–8), the most potent family member 
in  clonogenic  assays  (4)  (with  sub-nanomolar  IC70  values),  to  G  residues  of  duplex  DNA.  An  X-ray 
crystallographic analysis of a 2:1 complex of trioxacarcin A and an 8-mer duplex DNA oligonucleotide (8) 
reveals that the structure has features related to the (2:1) nogalamycin-DNA complex (9), with the linear 
aromatic cores of both small molecules bound intercalatively through the base stack and sugar residues 
positioned in the major and minor grooves, but unlike nogalamycin, trioxacarcin A covalently modifies the 
DNA duplex, by reaction of the spiro-epoxide with N7 of a flanking G residue as nucleophile (8). Other 
structurally distinct natural products families appear to function by pathways which may be mechanistically 
related (10, 11). 
To  realize  their  full  potential  as  chemotherapeutic  agents  and  to  enable  a  broader  study  of  the 
trioxacarcin class of DNA-binding molecules, we sought to develop a synthetic route that would allow for 
the  preparation  of  a  wide  array  of  new  trioxacarcins  in  amounts  sufficient  for  biological  evaluation. 
Towards this end and as a strategic objective, we determined to develop a route that approached maximal 
convergence, with the further specification that it be optimized toward bond-pair constructions between 
components of similar complexity at or near the final step of the sequence. Although the importance of 
convergence in synthesis has long been appreciated (12–21), highly condensed polycyclic targets such as 
the trioxacarcins frequently do not lend themselves to convergent simplification of the type specified, and 
synthesis  plans  that  might  meet  this  objective  can  be  stereochemically  ambiguous  and  (partly  as  a 
consequence) may offer modest probability of success. As an important counterpoint, however, the end 
value  of  a  route  that  successfully  achieves  a  high  degree  of  convergence  by  bond-pair  constructions 
between components of similar complexity is made evident by the rapidity with which large numbers of 
structural analogs can be prepared and by the diversity of compounds that can be synthesized through 
variation of the coupling partners (21–23). 4 
 
  To address natural and non-natural trioxacarcins broadly, we targeted for synthesis compound 2 and as 
its precursor the cyclic siloxane 3, differentially and orthogonally hydroxyl-protected derivatives of DC-45-
A2 (1).  By the retrosynthetic derivation outlined in Fig. 2, we envisioned that target 3 could be assembled 
in one step by a 1,3-dipolar cycloaddition reaction between the carbonyl ylide intermediate 4 and the 
aromatic aldehyde 5 (24, 25). Four diastereomeric cycloadducts can arise from the pairwise combinations 
of the two diastereofaces of reactants 4 and 5 (Fig. S1); only one (an endo cycloadduct) is stereochemically 
congruent with natural trioxacarcins. While each of the >20 prior examples of 1,3-dipolar cycloaddition 
reactions between a five-membered cyclic carbonyl ylide and an aromatic aldehyde was shown to proceed 
with exo selectivity (25, 26), we anticipated that different stereochemical outcomes might be achieved in 
the proposed cycloaddition reaction by variation of catalyst (both catalyzed and non-catalyzed carbonyl 
ylide−aldehyde  cycloadditions  are  known)  and/or  substrate  (such  as  by  modification  of  the  protective 
groups of the aldehyde component). We imagined that the carbonyl ylide intermediate 4 would derive in 
one step from the epoxy diazo diketone precursor 6, and that the aromatic aldehyde coupling component 5 
could be assembled in a second convergent bond-pair construction, by base-promoted cyclization of the 
cyanophthalide 7 with the substituted cyclohexenone 8. The three precursors 6, 7, and 8 were viewed to be 
components of similar synthetic complexity, as determined by analysis of the number of steps required for 
their preparation.  
Results and Discussion. 
   The densely functionalized epoxy diazo diketone 6, the precursor to the carbonyl ylide intermediate 4, 
was  synthesized  in  eight  steps,  as  shown  in  Fig.  3  (left-hand  column),  beginning  with  a  highly 
diastereoselective  auxiliary-controlled  Baylis−Hillman  reaction  between  the  Oppolzer  sultam-derived 
acrylimide  9  (1  equiv)  and  anhydrous  2,2-dimethoxyacetaldehyde  (3.0  equiv)  using  1,4-
diazabicyclo[2.2.2]octane (DABCO, 0.3 equiv) as catalyst in dichloromethane at 23 °C (16 h). The product 
of the reaction had incorporated two molecules of 2,2-dimethoxyacetaldehyde, and had expelled the sultam 
auxiliary by internal lactonization, as anticipated based on precedent (27).  Methanolysis of the resulting 
lactone  (triethylamine  in  methanol,  30  min,  23  °C)  afforded  the  corresponding  methyl  ester  (see  SI 5 
 
Appendix), shown to be ≥98% enantiomerically pure by capillary GC analysis. Hydroxyl protection with 
tert-butyldimethylsilyl trifluoromethanesulfonate (1.2 equiv) and  N,N-diisopropylethylamine (1.5 equiv) 
then afforded the tert-butyldimethylsilyl ether 10 (48% over 3 steps). Nucleophilic epoxidation of 10 at 0 
°C (4.5 h) in the presence of tert-butylhydroperoxide (2.0 equiv) and potassium tert-butoxide (0.1 equiv) 
provided selectively the anti epoxy ester 11 in 81% yield (anti : syn = 13 : 1) (28). Saponification of ester 
11  (THF−MeOH−H2O, LiOH, 0 °C) and activation of the resulting carboxylic acid by treatment with 
isobutylchloroformate (1.05 equiv) in the presence of Et3N (1.1 equiv) at −20 °C with gradual warming to 
−10 °C followed by addition of a solution of diazomethane in ether (~0.25 M, 2.0 equiv) and further 
warming to 23 °C provided after chromatographic purification on triethylamine-deactivated silica gel the 
epoxy  diazo  ketone  12  as  a  yellow  oil  (74%  yield,  2  steps).  Exposure  of  this  product  to 
triethylamine−trihydrofluoride  in  acetonitrile  led  to  efficient  cleavage  of  the  tert-butyldimethylsilyl 
protective group, affording the corresponding secondary alcohol in nearly quantitative yield. Oxidation 
with  Dess−Martin  periodinane  (1.1  equiv)  buffered  with  sodium  bicarbonate  then  afforded  the 
corresponding  epoxy  diazo  diketone  6  as  a  light  yellow  oil  in  77%  yield  (2  steps).  The  epoxy  diazo 
diketone 6 can be stored for several months without decomposition at −25 °C with care to exclude light.  
  The cyanophthalide 7 was prepared in eight steps by a highly practical route (Fig. 3, center column). 4-
Methyl salicylic acid (13, 50 g) was transformed in a sequence of five chemical transformations using 
conventional synthetic techniques and a single, final chromatographic purification step to afford the 3,4-
disubstituted  salicylamide  15  in  74%  yield  (57  g).  Protection  of  the  phenolic  hydroxyl  group  as  a 
methoxymethyl ether and subsequent directed metalation–formylation (29) provided the aldehyde 16 in 
94% yield. The latter intermediate was then transformed into the cyanophthalide 7 in 77% yield by brief 
exposure to cyanotrimethylsilane followed by extended treatment with glacial acetic acid (30, 31).  
  Two different routes were developed for the synthesis of the cyclohexenone fragment 8. The preferred 
route, shown in Fig. 3 (right-hand column, see SI Appendix for an alternate route), employed L-malic acid 
as starting material and proceeded through a known four-step sequence to the lactone 17 (Scheme 3). The 
latter product was transformed into the aldehyde 18 in 70% yield (2 steps) by Weinreb amide formation 6 
 
(32)  followed  by  oxidation  with  aqueous  sodium  hypochlorite  (1.0  equiv)  in  the  presence  of  2,2,6,6-
tetramethylpiperidine-1-oxyl  (TEMPO)  (0.01  equiv)  and  potassium  bromide  (0.1  equiv).  Addition  of 
aldehyde 18 to a 1:1 mixture of divinylzinc (2.0 equiv) and the amino alkoxide ligand 19 (2.0 equiv) at  –70 
°C provided the 4S-alcohol 20 selectively (dr 12:1), by which we infer that the substrate had reacted via 
bidendate coordination to the organometallic reagent (33). The product was susceptible to lactonization and 
so  was  protected  immediately  as  the  4-methoxybenzyl  ether  (21)  using  4-methoxybenzyl 
trichloroacetimidate (2.0 equiv) and Sc(OTf)3 as catalyst (0.03 equiv, 57% yield over 2 steps, 12:1 mixture 
of C4 diastereomers, 17.8-g scale). Addition of vinylmagnesium bromide (3.0 equiv) to amide 21 provided 
the  divinyl  ketone,  which  underwent  smooth  ring-closing  metathesis  in  the  presence  of  the  second-
generation Hoveyda−Grubbs ruthenium alkylidene catalyst (34) at 55 °C, affording the diastereomerically 
pure cyclohexenone coupling component 8 in 75% yield after chromatographic purification. 
  In the first of two late-stage ring-forming (bond-pair) coupling reactions, components 7 and 8 were 
combined in a Kraus−Sugimoto cyanophthalide annulation reaction (35). Thus, addition of a solution of 
enone 8 (1 equiv) to a cold solution of the cyanophthalide anion obtained by deprotonation of 7 (1.0 equiv) 
with lithium  tert-butoxide  (3.0  equiv)  in  tetrahydrofuran  at  –78  °C  led  to  rapid  formation  of  Michael 
addition product(s) (based on tlc analysis, not characterized); upon warming to –40 °C these underwent 
cyclization to form a single dihydroquinone phenolate, which was trapped in situ by monomethylation with 
dimethylsulfate (–26→23 °C).  The anthrone methyl ether 22 was obtained in 57% yield (3-g scale, yellow 
foam) after chromatographic isolation, a process facilitated by the long-wavelength UV absorption of the 
product,  with  blue-green  fluorescence,  a  characteristic  of  the  trioxacarcins.  Oxidative  cleavage  of  the 
alkenyl  side-chain  at  0  °C  (NaIO4,  K2OsO4⋅2H2O,  2,6-lutidine)  (36)  then  provided  the  corresponding 
aldehyde as an orange foam (69% yield). The methoxymethyl (MOM) protective group was selectively 
removed upon treatment of the latter product with B-bromocatecholborane (2.0 equiv), affording an air-
sensitive bis-phenol intermediate (89% yield)
 as a yellow foam. Silylation (t-Bu2SiCl2, HOBt, DIPEA, 55 
°C) (37) then provided the much more stable di-tert-butylsiloxane derivative 5 (50% yield), the substrate 
for final coupling. 7 
 
The fully oxygenated polycyclic skeleton of the trioxacarcins was assembled in one step by slow addition 
(syringe pump, 2 h) of a solution of the epoxy diazo diketone 6 (3.0 equiv, 2.26 M in dichloromethane) to a 
stirring suspension of aldehyde 5 (1 equiv, 0.75 M in dichloromethane), rhodium(II) acetate  (0.05 equiv), 
and powdered, activated 4Å molecular sieves at 23 °C. After filtration to remove the rhodium catalyst, the 
filtrate was concentrated, and the residue was purified by rp-HPLC to provide in 63% yield a mixture of 
diastereomeric cycloadducts in which the two endo diastereomers (3 and 23) greatly predominated (Fig. 3 
and S1). Pure samples of the individual diastereomers were obtained for spectroscopic analysis (see SI 
Appendix), but for preparative purposes it proved to be much more practical to separate the diastereomers 
after cleavage of the cyclic di-tert-butylsiloxane protective group (triethylamine–trihydrofluoride, 23 °C, 15 
min), where the endo diastereomers alone underwent spontaneous hemiketalization; these products, both 
obtained as bright yellow oils, were easily separated by rp-HPLC [24, 52 mg (36% yield) and 2, 48 mg 
(34% yield)]. Variation of the catalyst was indeed found to greatly influence the stereochemical outcome of 
the cycloaddition. For example, cycloaddition of 5 and 6 in the presence of copper(I) tetrakis(acetonitrile) 
afforded as the major product an exo diastereomer (46%) that represented only 14% of the diastereomeric 
product distribution when rhodium(II) acetate was used as catalyst. While we believe it likely that the 
efficiency and stereoselectivity of formation of the desired endo cycloadduct (3) may be improved by 
further  exploration  of  different  catalysts,  in  its  present  form  the  rhodium(II)  acetate-catalyzed 
transformation  provides  more  than  sufficient  quantities  of  material  for  biological  evaluation  and 
mechanistic  study.  Two-step  deprotection  of  endo  hemiketal  2  (DDQ;  triethylamine−trihydrofluoride) 
afforded synthetic DC-45-A2 (1) as a bright yellow powder (23 mg, 70% yield). Spectroscopic data for the 
synthetic substance were fully consistent with those reported for the natural product (5). Crystallization of 
synthetic DC-45-A2 from ethyl acetate–hexanes provided a single crystal suitable for X-ray diffraction 
analysis;  two  representations  of  the  three-dimensional  structure  obtained  are  depicted  in  Fig.  3.  This 
structure, the first of any trioxacarcin with an intact epoxide, conforms fully with that proposed for the 
natural product (5) and shows that the spiro-epoxide is ideally aligned for opening by a G-residue stacked 
upon the π-face of the tricyclic core. It is revealing that similar two-step deprotection of the stereoisomeric 8 
 
endo hemiketal 24 (with the more electrophilic carbon of the spiro-epoxide oriented away from the tricyclic 
aromatic core) gave rise to a chlorohydrin derivative (25%), presumably arising from ring-opening of the 
spiro-epoxide by chloride ion during workup, as well as the expected spiro-epoxide, iso-DC-45-A2 (25, 
22%, depicted in Fig. 4 A). No such opening was observed with DC-45-A2. In contrast, in experiments 
evaluating the reactions of DC-45-A2 (1) and iso-DC-45-A2 with the G residue of a known DNA substrate 
for alkylation by trioxacarcin A (7), iso-DC-45-A2 was found to be unreactive whereas 1 readily alkylated 
the DNA duplex, as discussed below.  
  We measured IC50 values of DC-45-A2, iso-DC-45-A2, and a fully synthetic analog, dideoxy-DC-45-A2 
(26), which we prepared by the six-step route outlined in Fig. 3 without variation, save for the use of 2-
cyclohexen-1-one as starting material in place of the substituted cyclohexenone coupling component 8, in 
HeLa and H460 cell lines (Fig. 4 A). DC-45-A2 inhibited the growth of both cell lines at micromolar 
concentrations. Dideoxy-DC-45-A2 was found to be a more potent growth inhibitor, with sub-micromolar 
IC50 values, and iso-DC-45-A2 was found to be inactive. Both DC-45-A2 and dideoxy-DC-45-A2 were 
found  to  modify  a  self-complementary  12-mer  duplex  oligonucleotide  containing  a  single  (central)  G 
residue  (7)  at  23  ºC,  as  determined  by  non-denaturing  polyacrylamide  gel  electrophoresis  with  in-gel 
fluorescence  detection  as  well  as  LC-MS  experiments,  albeit  with  different  rates  and  efficiencies  of 
alkylation (Fig. 4 B–D). While alkylation of the DNA duplex by DC-45-A2 proceeds with a half-life of 
hours  at  23  °C,  the  dideoxy-analog  reacts  with  the  DNA  duplex  within  minutes  at  23  °C  and  with 
apparently greater efficiency (Fig. 4 C and D). Iso-DC-45-A2 was not observed to modify the same DNA 
duplex under any conditions examined. 
  Heretofore, antiproliferative effects of non-glycosylated trioxacarcins such as DC-45-A2 have not been 
reported, so far as we are aware, nor has their chemistry with deoxyribonucleic acids been studied. Our 
findings  suggest  that  the  non-glycosylated,  rigid  polycyclic  framework  of  DC-45-A2,  with  a  naturally 
configured spiro-epoxide function, comprises structural features necessary and sufficient to provide an 
electrophile capable of alkylating G residues of duplex DNA, and that substantial variation in the rate, 
efficiency, and perhaps sequence specificity of DNA alkylation (not evaluated here) might be achieved by 9 
 
substitution upon this framework, which need not necessarily involve glycosylation. Structural variations 
by the convergent route reported can be achieved in two distinct ways, which together should allow for 
multiplicative  enhancement  of  the  pool  of  synthetic  trioxacarcins.  First,  selective  derivatization  of  the 
hydroxyl groups should be feasible by virtue of their orthogonal protection. Second, more deep-seated 
structural changes can be achieved by variation of any of the three coupling components (exemplified by 
the  synthesis  of  dideoxy-DC-45-A2  (26)  above).  We  believe  that  the  route  to  trioxacarcins  described 
enables  a  comprehensive  and  broad  evaluation  of  trioxacarcin-based  structures  as  potential 
chemotherapeutic agents, and provides a viable basis for their production on scales necessary to support 
clinical evaluation should preclinical studies support such advancement. 
 
Materials and Methods 
General. Experimental procedures and spectral data for all compounds created for this study can be found 
in the SI Appendix. 
Preparation  of  DC-45-A2  (1).  2,3-Dichloro-5,6-dicyanobenzoquinone  (17.4  mg,  76.7  µmol,  1.2 
equiv) was added to a vigorously stirring, biphasic solution of differentially protected DC-45-A2 (2) (48 
mg, 63.8 µmol, 1 equiv) in dichloromethane (1.3 mL) and water (130 µL) at 23 °C. The reaction flask was 
covered with aluminum foil to exclude light. Over the course of 5 h, the reaction mixture was observed to 
change  from  myrtle  green  to  lemon  yellow.  The  product  solution  was  partitioned  between  saturated 
aqueous sodium chloride solution (5 mL) and dichloromethane (50 mL). The layers were separated. The 
organic  layer  was  dried  over  sodium  sulfate.  The  dried  solution  was  filtered  and  the  filtrate  was 
concentrated.  The  residue  (1  equiv,  see  above)  was  dissolved  in  acetonitrile  (1.3  mL),  and 
triethylamine−trihydrofluoride (208 µL, 1.28 mmol, 20 equiv) was added at 23 °C. The reaction flask was 
covered with aluminum foil to exclude light. After 13.5 h, the reaction mixture was partitioned between 
saturated  aqueous  sodium  chloride  solution  (10  mL)  and  dichloromethane  (50  mL).  The  layers  were 
separated. The organic layer was dried over sodium sulfate. The dried solution was filtered and the filtrate 10 
 
was concentrated. The residue was purified by preparatory HPLC to provide 23 mg of the product, DC-45-
A2 (1), as a bright yellow powder (70%).  
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Fig. 1. Representative trioxacarcins and the anthracycline antibiotics daunomycin and nogalamycin. 12 
 
Fig. 2. Target identification and retrosynthetic analysis. 
Fig. 3. A multiply convergent route for the synthesis of trioxacarcins. 
Fig. 4. Synthetic non-glycosylated trioxacarcins, their antiproliferative activities in cultured human cancer 
cells, and DNA-modifying effects. (A) IC50 values for DC-45-A2, iso-DC-45-A2, and dideoxy-DC-45-A2 
measured in HeLa (cervical cancer) and H460 (lung cancer) cells lines. (B) Images of TBE gels of the 
products of the reaction of the self-complementary duplex 12-mer d(AATTACGTAATT) (100 µM) with 
DC-45-A2 (lane 2, 100 µM), iso-DC-45-A2 (lane 3, 100 µM), or dideoxy-DC-45-A2 (lane 4, 100 µM) for 
2 h at 23 ºC; visualized with ethidium bromide and by in-gel fluorescence. (C) Images of TBE gels of the 
products of the reaction of the self-complementary duplex 12-mer d(AATTACGTAATT) (100 µM) with 
DC-45-A2 or dideoxy-DC-45-A2 (25 µM) at 23 °C for the indicated times; visualized by in-gel 
fluorescence. (D) LC/MS chromatograms of reaction mixtures of the self-complementary duplex 12-mer 
d(AATTACGTAATT) (100 µM) and i) DC-45-A2 (100 µM), ii) iso-DC-45-A2 (100 µM), or iii) dideoxy-
DC-45-A2 (100 µM) after 24 h at 23 ºC; panel iv depicts the LC/MS chromatogram of the reaction mixture 
of the self-complementary duplex 12-mer d(AATTACGTAATT) (100 µM) and dideoxy-DC-45-A2 (100 
µM) after 24 h at 23 ºC followed by the addition of piperidine (1 M) and heating for 30 min at 95 ºC; l = 
(AATTACGTAATT); o = (AATTACGTAATT • 1); u = (AATTACGTAATT • 26); n = (pTAATT); 
ﾡ = (AATTACp). 
 